Endothelium‑dependent vasodilation effects of Panax notoginseng and its main components are mediated by nitric oxide and cyclooxygenase pathways

Wang,Yanyan; Ren,Yu; Xing,Leilei; Dai,Xiangdong; Liu,Sheng; Yu,Bin; Wang,Yi

doi:10.3892/etm.2016.3890

Endothelium‑dependent vasodilation effects of Panax notoginseng and its main components are mediated by nitric oxide and cyclooxygenase pathways

Authors:
- Yanyan Wang
- Yu Ren
- Leilei Xing
- Xiangdong Dai
- Sheng Liu
- Bin Yu
- Yi Wang
View Affiliations

Affiliations: Institute of Traditional Chinese Medicine Research, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China, Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, P.R. China
Published online on: November 9, 2016 https://doi.org/10.3892/etm.2016.3890
Pages: 3998-4006
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Panax notoginseng, a traditional Chinese herbal medicine, has been used for the treatment of cardiovascular diseases. The main bioactive components of this species are Panax notoginseng saponins (PNS). The present study aimed to investigate the effects of PNS and five of its main components (ginsenosides Rg1, Re, Rb1 and Rd, and notoginsenoside R1) on rat aorta rings pre‑contracted with norepinephrine (NE) and to determine the underlying mechanism of action. Isolated aorta rings (with or without intact endothelium) from adult male Wistar rats were stimulated with NE to induce vasoconstriction, and subsequently treated with different concentrations of PNS and its five main components (Rg1, Re, Rb1, R1 and Rd) separately. This procedure was repeated after pre‑incubation with the nitric oxide (NO) synthase inhibitor NG‑nitro‑L‑arginine methyl ester (L‑NAME), the guanylate cyclase inhibitor 1H‑[1,2,4]oxadiazolo[4,3‑a]quinoxalin‑1‑one (ODQ) and the cyclooxygenase (COX) inhibitor indomethacin (INDO), in order to elucidate the mechanism of action of PNS and its components. The results demonstrated that PNS and the components Rg1, Re, Rb1 and R1, but not Rd, induced vessel relaxation in a concentration‑dependent manner when the endothelium lining was intact. NO synthase inhibitor L‑NAME and guanylate cyclase inhibitor ODQ attenuated the diastolic effects of PNS, Rg1, Re, Rb1 and R1 in aortic rings with intact endothelium. By contrast, INDO, a known COX inhibitor weakened the vasodilation effects of PNS, Re and Rb1 but demonstrated no effect on Rg1 and R1. In conclusion, PNS and two of its main components (Re and Rb1) exert vasodilating effects through the NO and COX pathways.

View Figures

View References

1	Kim SJ, Lee J, Jee SH, Nam CH, Chun KH, Park IS and Lee SY: Cardiovascular Risk Factors for Incident Hypertension in the Prehypertensive Population. Epidemiol Health. 32:e20100032010. View Article : Google Scholar : PubMed/NCBI
2	Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB and Levy D: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 345:1291–1297. 2001. View Article : Google Scholar : PubMed/NCBI
3	Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr and Roccella EJ: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 289:2560–2572. 2010. View Article : Google Scholar
4	Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, et al: ESH-ESC guideline for the management of hypertension. Herz. 31:331–338. 2006. View Article : Google Scholar : PubMed/NCBI
5	Toda N, Nakanishi S and Tanabe S: Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: Therapeutic implications. Br J Pharmacol. 168:519–533. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kopincova J, Puzserova A and Bernatova I: Chronic low-dose L-NAME treatment effect on cardiovascular system of borderline hypertensive rats: Feedback regulation? Neuro Endocrinol Lett. 29:784–789. 2008.PubMed/NCBI
7	Tsai AL, Berka V, Sharina I and Martin E: Dynamic ligand exchange in soluble guanylyl cyclase (sGC): Implications for sGC regulation and desensitization. J Biol Chem. 286:43182–43192. 2011. View Article : Google Scholar : PubMed/NCBI
8	Feelisch M, Kotsonis P, Siebe J, Clement B and Schmidt HH: The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol. 56:243–253. 1999.PubMed/NCBI
9	Kasznicki J and Wiktorowsha-Owczarek A: Effects of indomethacin on hymodynamic parameters after intravenous administration of propranolol and enalaprilat in rabbits. Pol J Pharmacol. 53:487–493. 2001.PubMed/NCBI
10	Zhang XY, Guo SL and Lv GY: Research progress of the mechanism of antihypertensive Traditional Chinese Medicine. Zhejiang Zhong Yi Yao Da Xue Xue Bao. 29:84–86. 2005.(In Chinese).
11	Wang HQ, Yang HJ and Li ZH: Research progress of antihypertension drug. Jibing Jiance Yu Kongzhi. 1:35–38. 2013.(In Chinese).
12	Bai Y: Evaluation and rational application of antihypertensive drugs. Chifeng Xue Yuan Xue Bao. 88–89. 2007.(In Chinese).
13	Guo HB, Cui XM, An N and Cai GP: Sanchi ginseng (Panax notoginseng (Burkill) F. H. Chen) in China: Distribution, cultivation and variations. Genet Resour Crop Evol. 57:453–460. 2010. View Article : Google Scholar
14	Ng TB: Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol. 58:1007–1719. 2006. View Article : Google Scholar : PubMed/NCBI
15	He L, Chen X, Zhou M, Zhang D, Yang J, Yang M and Zhou D: Radix/rhizoma notoginseng extract (Sanchitongtshu) for ischemic stroke: A randomized controlled study. Phytomedicine. 18:437–442. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zheng X, Deng YH, Feng Y, Liu Y, Yang L, Huang Y, Sun J, Liang W and Guan Y: Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers. J Clin Pharmacol. 50:285–292. 2010. View Article : Google Scholar : PubMed/NCBI
17	Liu J, Wang Y, Qin L, Yu Y and Wang C: Saponins of Panax notoginseng: Chemistry, cellular targets and therapeutic opportunities in cardiovascular diseases. Expert Opin Investig Drugs. 23:523–539. 2014. View Article : Google Scholar : PubMed/NCBI
18	Uzayisenga R, Ayeka PA and Wang Y: Anti-diabetic potential of Panax notoginseng saponins (PNS): A review. Phytother Res. 28:510–516. 2014. View Article : Google Scholar : PubMed/NCBI
19	Cicero AF, Bandieri E and Arletti R: Orally administered Panax notoginseng influence on rat spontaneous behaviour. J Ethnopharmacol. 73:387–391. 2000. View Article : Google Scholar : PubMed/NCBI
20	Huang YS, Yang ZC, Yan BG, Hu XC, Li AN and Crowther RS: Improvement of early postburn cardiac function by use of Panax notoginseng and immediate total eschar excision in one operation. Burns. 25:35–41. 1999. View Article : Google Scholar : PubMed/NCBI
21	Wang XJ, Ichikawa H and Konishi T: Antioxidant potential of qizhu tang, a Chinese herbal medicine, and the effect on cerebral oxidative damage after ischemia reperfusion in rats. Biol Pharm Bull. 24:558–563. 2001. View Article : Google Scholar : PubMed/NCBI
22	Li XH and Li SH: Effects of total saponins of Sanchi (Panax pseudo-ginseng var. notoginseng) on TNF, NO and its mechanisms. Zhong Cao Yao. 307:514–515. 1999.(In Chinese).
23	Liu S and Chen JX: Study on effects of raw and cooked Panax notoginseng on blood lipids. Acta Pharmacology Sinica. 5:100–103. 1984.
24	Chen W, Dang Y and Zhu C: Simultaneous determination of three major bioactive saponins of Panax notoginseng using liquid chromatography-tandem mass spectrometry and a pharmacokinetic study. Chin Med. 5:122010. View Article : Google Scholar : PubMed/NCBI
25	Wang JR, Yao LF, Gao WN, Liu Y, Yick PW, Liu L and Jiang ZH: Quantitative comparison and metabolite profiling of saponins in different parts of the root of Panax notoginseng. J Agric Food Chem. 62:9024–9034. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wang L, Li Z, Zhao X, Liu W, Liu Y, Yang J, Li X, Fan X and Cheng Y: A network study of Chinese medicine xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget and multipathway. Evid Based Complement Alternat Med. 2013:6523732013.PubMed/NCBI
27	Qin F, Yu SL, Zheng Y and Gao YH: Simultaneous determination of ginsenoside Rg1 and ginsenoside Re in total saponins of fibrous roots of Panax notoginseng by HPLC-MS/MS. Zhongguo Yao Fang. 21:2922–2924. 2010.(In Chinese).
28	Zhang C, Bao J, Li X and Zheng Y: HPLC determination of the amount of ginsenosides in different parts of Panax ginseng C.A.Mey. and P. quiquefolius L. and P. notoginseng (Burk) F.H.Chen. Yao Wu Fen Xi Za Zhi. 25:1190–1194. 2005.(In Chinese).
29	Jiang YQ, Wang Q, Ma SP and Danf XD: Quantitative determination of saponins in the root of Panax pseudoginseng var.notoginseng by HPLC-ELSD and UV spectrophotometry. Zhong Cao Yao. 31:737–739. 2000.(In Chinese).
30	Wan JB, Wang YT and Li SP: Sanqi (Panax notoginseng)Pharmacological Activity-Based Quality Control of Chinese Herbs. Li SP and Wang YT: Nova Science Publishers; New York: pp. 179–203. 2008
31	Wan JB, Zhang QW, Ye WC and Wang YT: Quantification and separation of protopanaxatriol and protopanaxadiol type saponins from Panax notoginseng with macroporous resins. Sep Pur Tech. 60:198–205. 2008. View Article : Google Scholar
32	Xu SY: Methodology of Pharmacological Experiments. 2nd. People's Health Publishing House; Beijing: pp. 886–887. 1994, (In Chinese).
33	Qiao CL, Ding YF and Yang CR: Pharmacologic research progress of notoginseng total saponins. Zhongguo Xian Dai Zhong Yao. 11:25–30. 2012.(In Chinese).
34	Guo WJ, Yang M, Zhu JG, et al: New progress on pharmacological study of Panax notoginsenoside on the cardiovascular effects. Xian Dai Shi Pin Yu Yao Pin Za Zhi. 2:1–4. 2007.(In Chinese).
35	Cheng Y, Shen LH and Zhang JT: Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin. 26:143–149. 2005. View Article : Google Scholar : PubMed/NCBI
36	Zhang JT: Nootropic mechanisms of ginsenoside Rg1-influence on neuronal plasticity and neurogenesis. Yao Xue Xue Bao. 40:385–388. 2005.(In Chinese). PubMed/NCBI
37	Zhong ZD, Wang CM, Wang W, Shen L and Chen ZH: Major hypoglycemic ingredients of Panax notoginseng saponins for treating diabetes. Sichuan Da Xue Xue Bao Yi Xue Ban. 45:235–239. 2014.(In Chinese). PubMed/NCBI
38	Peng L, Sun S, Xie LH, Wicks SM and Xie JT: Ginsenoside Re: Pharmacological effects on cardiovascular system. Cardiovasc Ther. 30:e183–1e88. 2012. View Article : Google Scholar : PubMed/NCBI
39	Ye R, Zhao G and Liu X: Ginsenoside Rd for acute ischemic stroke: Translating from bench to bedside. Expert Rev Neurother. 13:603–613. 2013. View Article : Google Scholar : PubMed/NCBI
40	He K, Yan L, Pan CS, Liu YY, Cui YC, Hu BH, Chang X, Li Q, Sun K, Mao XW, et al: ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. Am J Physiol Heart Circ Physiol. 307:H1764–H1776. 2014. View Article : Google Scholar : PubMed/NCBI
41	Wang H, Qu JT, Zhao X, Guo Y and Mao HP: Vasodilator effect of oroxylin A on thoracic aorta isolated from rats. Zhong Xi Yi Jie He Xue Bao. 10:880–885. 2012.(In Chinese). View Article : Google Scholar : PubMed/NCBI
42	Martinsen A, Baccelli C, Navarro I, Abad A, Quetin-Leclercq J and Morel N: Vascular activity of a natural diterpene isolated from Croton zambesicus and of a structurally similar synthetic trachylobane. Vascul Pharmacol. 52:63–69. 2010. View Article : Google Scholar : PubMed/NCBI
43	McFadzean I and Gibson A: The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. Br J Pharmacol. 135:1–13. 2002. View Article : Google Scholar : PubMed/NCBI
44	Slish DF, Arvigo R and Balick MJ: Alseis yucatanensis: A natural product from Belize that exhibits multiple mechanisms of vasorelaxation. J Ethnopharmacol. 92:297–302. 2004. View Article : Google Scholar : PubMed/NCBI
45	Stone DJ and Johns RA: Endothelium-dependent effects of halothane, enflurane and isoflurane on isolated rat aortic vascular rings. Anesthesiology. 71:126–132. 1989. View Article : Google Scholar : PubMed/NCBI
46	Furchgott RF: The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 24:175–194. 1984. View Article : Google Scholar : PubMed/NCBI
47	Vanhoutte PM, Rubanyi GM, Miller VM and Houston DS: Modulation of vascular smooth muscle contraction by the endothelium. Annu Rev Physiol. 48:307–320. 1986. View Article : Google Scholar : PubMed/NCBI
48	Corvol P, Alhenc-Gelas F and Soubrier F: The vascular endothelium, a site of production and metabolism of vasoactive peptides. Med Sci (Paris). 9:1050–1060. 1993.(In French). View Article : Google Scholar
49	Negro R: Endothelial effects of antihypertensive treatment: Focus on irbesartan. Vasc Health Risk Manag. 4:89–101. 2008. View Article : Google Scholar : PubMed/NCBI
50	Hellsten Y, Nyberg M, Jensen LG and Mortensen SP: Vasodilator interactions in skeletal muscle blood flow regulation. J Physiol. 590:6279–6305. 2012. View Article : Google Scholar
51	Wang GZ, Luo XF, Sun B, Hou YL, Li LP, Zheng DD and Qiao GF: Effects and mechanism of the flavonoid glycoside of Polygonum aviculare L. on vascular endothelium relaxation. Haerbin Yi Ke Da Xue Xue Bao. 4:315–318. 2010.(In Chinese).
52	Li YJ, Zhou JW and Bin K: The diastolic mechanism of Gualou Xiebai Banxia Decoction. Zhong Yao Yao Li Yu Lin Chuang. 4:5–7. 2010.(In Chinese).
53	Li XL, Zou XM, Nie G, Song ML and Li G: Roles of neuronal nitric oxide synthase and inducible nitric oxide synthase in intestinal transplantation of rats. Transplant Proc. 45:2497–2501. 2013. View Article : Google Scholar : PubMed/NCBI
54	Denninger JW and Marletta MA: Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta. 1411:334–350. 1999. View Article : Google Scholar : PubMed/NCBI
55	Marinko M, Novakovic A, Nenezic D, Stojanovic I, Milojevic P, Jovic M, Ugresic N, Kanjuh V, Yang Q and He GW: Nicorandil directly and cyclic GMP-dependently opens K+ channels in human bypass grafts. J Pharmacol Sci. 128:59–64. 2015. View Article : Google Scholar : PubMed/NCBI
56	Fang WT, Li HJ, Zhou LS and Su LQ: Prostacyclin signal pathway: Research advances. Guo Ji Yao Xue Yan Jiu Za Zhi. 4:276–278. 2010.(In Chinese).
57	Zhou P, Wang HP and Jiang HD: The Extracts of Cortex Eucammiae induces both directly and endothelium-dependent relaxation in rat thoracic aorta. Zhongguo Xian Dai Ying Yong Yao Xue. 3:182–185. 2007.(In Chinese).